Cytogenetic aberrations in adult acute lymphoblastic leukemia—A population-based study

Emma Bergfelt Lennmyr¹,# | Marie Engvall²,# | Gisela Barbany³ | Linda Fogelstrand⁴,⁵ | Hanna Rhodin¹ | Helene Hallböök¹

¹ Department of Medical Sciences, Uppsala University, Uppsala, Sweden  
² Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden  
³ Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden  
⁴ Department of Clinical Chemistry, Sahlgrenska University Hospital, Gothenburg, Sweden  
⁵ Department of Laboratory Medicine, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden

Correspondence  
Emma Bergfelt Lennmyr, Department of Medical Sciences, Uppsala University, Uppsala.  
Email: emma.lennmyr@medsci.uu.se

#Emma Bergfelt Lennmyr and Marie Engvall share first name authorship.

Abstract  
Cytogenetic aberrations are recognized as important prognostic factors in adult acute lymphoblastic leukemia (ALL), but studies seldom include elderly patients. From the population-based Swedish ALL Registry, we identified 728 patients aged 18–95 years, who were diagnosed with ALL 1997–2015 and had cytogenetic information. Registry data were complemented with original cytogenetic reports. BCR-ABL1 was the most recurrent aberration, with a frequency of 26%, with additional cytogenetic alterations in 64%. KMT2A rearrangement was the second most frequent aberration found in 7%. Low hypodiploidy-near triploidy and complex karyotype had negative impact, while t(1;19);TCF3-PBX1 showed positive impact on overall survival. However, after correction for age only complex karyotype remained significant.

KEYWORDS  
ALL, clinical cytogenetics, clinical hematology, cytogenetics of leukemia

1 | INTRODUCTION

Information regarding cytogenetic aberrations has been recognized as important for prognosis in acute lymphoblastic leukemia (ALL) for decades [1, 2]. Thus, to genetically characterize ALL at diagnosis is mandatory and has implications for choice of treatment [3]. Still, genetic reference studies in adult ALL are infrequent and often derived from clinical trials with a corresponding selection bias excluding or not completely representing elderly ALL patients. In 2010, Moorman et al. [4] described the genetic findings in a cohort of 349 patients with adult ALL diagnosed in the northern part of England but apart from this, population-based studies are scarce.

The aim of this study was to describe the panorama of genetic aberrations found in adult ALL, and their association with prognosis in a population-based setting.

2 | MATERIALS AND METHODS

The Swedish ALL Registry harbors a dual reporting system, where both pathologists and clinicians are required to report all adult patients who are diagnosed with ALL [5]. In 2019, we published results on outcome, including frequency of BCR-ABL1 and treatment, from the registry of 933 patients diagnosed from 1997 to 2015 [5]. In this paper, we have scrutinized the reported cytogenetic information in the registry for this cohort and supplemented the registered information with the original cytogenetic reports retrieved from the six cytogenetic facilities located at the University Hospitals in Sweden.

Definitions of genetic aberrations, methodology, and statistical analysis used are described in Supporting Information. For all comparisons, normal karyotype with ≥20 analyzed metaphases was used as comparator. The study was conducted in accordance with the
3 | RESULTS

The median age of the 933 patients reported to the registry was 53 years (range 18–95). Details regarding immunophenotype and treatment are described in the previous registry publication [5]. Out of the 933 patients, 205 did not have any reported cytogenetic analysis from diagnosis. These patients had a median age of 66 years (range 18–95); 53% were male and median date of diagnosis was May 2003. Twelve had some genetic analysis performed but not at the time of diagnosis and 23 had an inconclusive or failed analysis. One patient had been diagnosed abroad and for the remaining 170 patients no cytogenetic analysis was done at all.

The 728 patients with any cytogenetic analysis had a median age of 50 years (range 18–90); 57% were male and the median date of ALL diagnosis was June 2008. The immunophenotypes were distributed in B-ALL 72%, T-ALL 15%, Burkitt leukemia 4%, and ALL NOS 9%. Sixty-four patients with a sole negative test for BCR-ABL1 and/or KMT2A-rearrangement (KMT2A-r) were included only in the frequency analysis for these specific aberrations. For the remaining cohort of 664 patients, the main cytogenetic abnormalities are described in Table 1, divided by immunophenotype and age. According to the clinical registry report, remission inducing therapy was intended in 627 (94%) of the patients.

The translocation t(9;22)(q34;q11); BCR-ABL1 was the most frequent cytogenetic aberration, detected in 26% of investigated patients and predominantly associated with the B-ALL phenotype (Table 1). In patients with confirmed BCR-ABL1 fusion (n = 124), 72% harbored the BCR-ABL1 minor transcript (p190) (median age 57 years [range 19–87]), and 27% the BCR-ABL1 major (p210) transcript (median age 45 years [range 21–76]). One patient had no specified transcript.

Additional cytogenetic abnormalities (ACA) to BCR-ABL1 were frequent and found in 64% of the patients, 19% had no ACA, and 17% were not examined with anything but a targeted investigation or had a normal karyotype with ≥20 metaphases (n = 6). The most common ACA was an additional Philadelphia chromosome +deriv(22)(t(9;22) (n = 32), followed by −7 (n = 14) and +8 (n = 11). Of these, eight had a combination of +deriv(22)(t(9;22) and −7/+8. Having a p190 versus p210 transcript did not significantly impact overall survival (OS), nor did the presence of an ACA, or any of the three most frequent ACA versus no detected ACA (data not shown, analysis performed with correction for age).

KMT2A-r was the second most frequent aberration, found in 46 out of 647 investigated patients (7%). Information about the fusion partner gene was available for 43 of 46 patients and the majority (n = 33, 77%) had a KMT2A-AFF1 fusion arising from the t(4;11)(q21;q23) translocation (median age 48, range 18–74 years). The translocation t(11;19)(q23;p13), where KMT2A can have several fusion partners, was found in six (14%) patients (median age 63, range 39–73 years). CBL and ARHGEF12 as partner genes to KMT2A as well as t(11;11)(p32;q23) and t(4;11;15) were found in one case each. No difference was observed regarding OS between t(4;11) and t(11;19), analysis made with and without correction for age.

The 5-year OS and hazard ratios (corrected for age) are shown in Table 2. Among the “other” cytogenetic aberrations, dic(7;9)(p11–13;p11) was found in three B-ALL cases aged 51–73 years. Interestingly, all three were alive at follow-up, 7–15 years after diagnosis. t(1;19);TCF3-PBX1 was confirmed in seven patients, with a female predominance. The OS was higher compared to normal karyotype but when corrected for age it lost significance. Six of the seven patients were alive at follow, 2–10 years after diagnosis.

Patients with high hyperdiploidy (HeH) ALL had lower WBC at diagnosis. When corrected for age, HeH did not appear as a favorable cytogenetic risk group, with a hazard ratio of 1.36 for OS (n.s.). Complex karyotype and low hypodiploidy-near triploidy (Ho-Tr) correlated with inferior OS as well as with a high median age. After correction for age, only complex karyotype remained as a negative factor for OS. In the group with complex karyotype, potential loss of the TP53 gene was found in five of 22 cases.

4 | DISCUSSION

Cytogenetic aberrations are important for risk classification in adult ALL, with BCR-ABL1 being the most frequent aberration. Cytogenetic alterations affect the choice of treatment, which in Sweden is stipulated by national guidelines. In our study, the majority of BCR-ABL1 cases harbored ACA, with an additional derivative chromosome 22, −7, and +8 being most common, as previously reported [6]. The impact of ACA reported in some studies [7–10] was not confirmed here, or in the study by Moorman et al. [6].

KMT2A-r is commonly recognized as a negative prognostic factor [11], but the negative impact on prognosis is not always retained in multiple variable analysis correcting for other factors [6, 12]. We did not find a difference in outcome for patients with KMT2A-r compared to those with normal karyotype, nor was there a difference in outcome for patients with different KMT2A-r subtypes. In Sweden, the chemotherapie regimen has included high-dose cytarabine, which is suggested beneficial for KMT2A-r in children [13]. In addition, allogeneic hematopoietic stem cell transplantation has been recommended for fit patients for the main part of the period, which might have influenced outcome. Yet, the relatively low number of patients could also have hampered the analyses.

HeH is well known as a favorable prognostic factor for children with ALL, but few data are available for adults. In our study, there was a trend toward younger age and lower WBC, but when correcting for age, HeH was not a favorable factor in adult ALL, confirming previous reports [6, 11, 14]. Atypical chromosomal gains compared to classical pediatric HeH [11] and the presence of two or more additional structural abnormalities [14] has previously been correlated to adverse survival in adult cohorts. This could indicate that pediatric and adult HeH are separate entities.
### TABLE 1  
Patient characteristics and cytogenetic findings in 664 patients

|                        | All  | B-ALL | T-ALL | Burkitt-leukemia NOS | 18–30 years | 31–50 years | 51–70 years | ≥71 years | Median age
\(e\)  
\(\text{(range)}\) | Males N  
\(e\) (%) | Median WBC
\(f\)  
\(\text{(range)}\) |
|-----------------------|------|-------|-------|-----------------------|-------------|-------------|-------------|-----------|-------------|
| Cohort with cytogenetic analysis\(a\) | 664  | 472   | 99    | 28                    | 65          | 152         | 181         | 228       | 103         | 51 (18–90)  | 381 (57)    | 14 (0.5–904) |
| BCR-ABL1\(b\)       | 176 (26) | 167(34) | 1    | –                     | 8 (13)      | 17 (11)     | 65 (33)     | 72 (31)   | 22 (22)     | 52 (19–87)  | 92 (52)     | 29 (0.7–477) **|
| Normal karyotype\(c\) \(≥\) 20 metaphases analyzed | 83 (12) | 52 (11) | 22 (22) | 3 (11) | 6 (9) | 20 (13) | 18 (10) | 34 (15) | 11 (11) | 53 (18–78) | 52 (63) | 10 (1–212) |
| No aberration, <20 metaphases analyzed | 39 (6)  | 27 (6) | 9 (9)  | 2 (7) | 1 | 9 (6) | 9 (5) | 14 (6) | 7 (7) | 56 (18–90) | 25 (64) | 9 (1–26) |
| KTM2A-r\(b\)        | 46 (7)  | 36 (8) | 2 (2)  | –                     | 8 (12)      | 7 (5)       | 15 (8)      | 16 (7)    | 8 (9)       | 54 (18–75)  | 17(37) ** | 114 (5–904) ** |
| t(8:14)\(e\)        | 30 (4)  | 5 (1)  | 2 (2)  | 19 (68) | 4 (6) | 5 (3) | 10 (6) | 9 (4) | 6 (6) | 53 (19–81) | 23 (67) | 11 (5–120) |
| HeH                  | 28 (4)  | 22 (5) | –      | 1 | 5 (8) | 15 (10) | 2 (1) | 7 (3) | 4 (4) | 28 (18–76) | 16 (57) | 4 (0.6–24) ** |
| Ho-Tr                | 27 (4)  | 23 (5) | 1      | –                     | 3 (5)       | 3 (2)       | 4 (2)       | 13 (6)    | 7 (7)       | 64 (18–80)  | 17 (63) | 6 (1–33)  |
| Complex karyotype    | 22 (3)  | 13 (3) | 2 (2)  | 2 (7) | 5 (8) | 2 (1) | 4 (2) | 10 (4) | 6 (6) | 62 (22–80) | 8 (36) | 4 (0.7–43) |
| Tetraploidy          | 8 (1)   | 2 (0.4) | 3 (3)  | –                     | 3 (5)       | 2 (1)       | 4 (2)       | 2 (1)     | –          | 37 (18–65)  | 3 (38) | 4 (2–71)  |
| t(1;19);TCF3-PBX11   | 7 (1)   | 6 (1)  | –      | –                     | 1           | 3 (2)       | 1           | 2 (1)     | 1           | 49 (22–76)  | 11 (14) | 20 (10–28) |
| Other                | 198 (30) | 119 (25) | 57 (58) | 1 | 21 (32) | 69 (45) | 49 (27) | 49 (22) | 31 (30) | 40 (18–87) | 127 (64) | 9 (0.5–395) |

**Abbreviations:** HeH, high hyperdiploidy; Ho-Tr, low hypodiploidy-near triploidy; NOS, not otherwise specified; WBC, white blood cell count.

*\(p < 0.05\)

**\(p < 0.01\)

\(a\)Excluding patients with negative FISH or PCR only examining BCR-ABL1 or KTM2A-r.

\(b\)Frequency of adequately examined patients (as described in Supporting Information); BCR-ABL1, \(n = 688\) and KTM2A-r, \(n = 647\) patients.

\(c\)Normal karyotype only including \(≥\) 20 metaphases.

\(d\)The group t(8:14) also includes t(2:8) and t(8:22).

\(e\)Comparison with normal karyotype as control.

\(f\)WBC only available for patients with diagnose 2007 – 2015. Comparison with normal karyotype as control.
**TABLE 2** Survival for different cytogenetic groups

| Cytogenetic Group                      | 5-year OS (95%CI)  | p (log-rank) | HR (95% CI)  | p       |
|---------------------------------------|--------------------|--------------|--------------|---------|
| BCR-ABL1                              | 41 (33–48)%        | 0.86         | 0.95 (0.68–1.31) | 0.75    |
| Normal karyotype, ≥20 metaphases       | 43 (32–54)%        | Control      | Control      |         |
| analyzed                               |                    |              |              |         |
| No aberration, <20 metaphases analyzed| 37 (22–52)%        | 0.50         | 1.20 (0.76–1.92) | 0.43    |
| KMT2A-r                               | 36 (22–51)%        | 0.09         | 1.40 (0.90–2.17) | 0.13    |
| t(8:14)b                              | 43 (26–61)%        | 0.74         | 1.13 (0.67–1.91) | 0.65    |
| HeH                                   | 49 (30–68)%        | 0.40         | 1.36 (0.75–2.46) | 0.31    |
| Ho-Tr                                 | 18 (4–33)%         | ＜0.01        | 1.55 (0.93–2.58) | 0.09    |
| Complex karyotype                     | 18 (2–34)%         | ＜0.01        | 2.05 (1.2–3.49) | ＜0.01  |
| Tetraploidy                           | 38 (4–71)%         | 0.57         | 1.98 (0.78–5.07) | 0.15    |
| t(1;19);TCF3-PBX1                     | 86 (60–100)%       | 0.03         | 0.16 (0.02–1.14) | 0.07    |
| Other                                 | 45 (38–52)%        | 0.49         | 1.07 (0.77–1.48) | 0.70    |

Abbreviations: CI, confidence interval; HeH, high hyperdiploidy; Ho-Tr, low hypodiploidy-near triploidy; HR, hazard ratio.

aCox regression adjusted for age.
bThe group t(8:14) also includes t(2;8) and t(8;22).
cHo-Tr HR (95% CI) 1.98 (1.20–3.26) p < 0.01 uncorrected for age.
dComplex karyotype HR (95% CI) 2.19 (1.29–3.70) p < 0.01 uncorrected for age.

Ho-Tr and t(1;19);TCF3-PBX1 impacted OS in the univariable analysis but lost significance when corrected for age. The groups included very few patients, precluding any firm conclusions.

The only negative cytogenetic risk factor that remained after correction for age was complex karyotype. This has been open to debate since the study by Moorman et al. [6] showed inferior survival, later confirmed by some [12] but not all study groups [11, 15]. One possible explanation could be specific alterations such as loss of p53; however, the frequency was too low to solely explain the impact of complex karyotype on prognosis. Complex karyotype has not been considered a high risk factor in Sweden, and thereby allografting has not been recommended upfront in cases with good initial response. In this material, it was done as upfront treatment for only eight of the 22 patients harboring a complex karyotype.

The strength of our study is that we report the frequency of genetic alterations found in adult ALL in a population-based manner with no upper age limit. The weakness is associated with the limited details concerning clinical data in the registry. Also, diagnostic procedures have rapidly evolved and cytogenetic diagnostics have reached standards that were not available for patients in the early part of the study period.

We conclude that complex karyotype is a previously debated negative prognostic factor in adult ALL. With treatment according to national guidelines, no other aberration including BCR-ABL1, KMT2A-r, or HeH impacted survival. Incorporating complex karyotype in future risk stratification should therefore be considered.

**ACKNOWLEDGMENTS**

We would like to thank the Swedish Adult ALL group and the ALL team at the Regional Cancer Center in Lund. We would also express our gratitude to the ALL Register chair holders Karin Karlsson and Anna Lübking and to the staff in Cytogenetic Units/Genetic Departments at the University Hospitals in Gothenburg, Linköping, Lund, Stockholm, Umeå, and Uppsala. The research was conducted with support from the Lions Cancer Foundation, Uppsala and the Uppsala University and Uppsala County Council/Region agreement on medical training and clinical research.

**AUTHOR CONTRIBUTIONS**

Emma Bergfelt Lennmyr and Helene Hallböök designed the study, analyzed statistics, and wrote the paper. Marie Engvall, Gisela Barbany, and Linda Fogelstrand evaluated and classified cytogenetic data and contributed to the writing of the paper. Hanna Rhodin collected and classified data. All authors critically reviewed and approved the final draft.

**CONFLICT OF INTEREST**

The authors declare no conflict of interest.

**ORCID**

Emma Bergfelt Lennmyr https://orcid.org/0000-0002-1737-5568

**REFERENCES**

1. Bloomfield CD, Goldman AI, Alimena G, Berger R, Borgstrom GH, Brandt L, et al. Chromosomal abnormalities identify high-risk and low-risk patients with acute lymphoblastic leukemia. Blood. 1986;67(2):415-20.
2. Hematologique GFdC. Cytogenetic abnormalities in adult acute lymphoblastic leukemia: correlation with hematologic findings and outcome. A Collaborative Study of the Group Francais de Cytogenetique Hematologique. Blood. 1996;87:3135-42.
3. Hoelzer D, Bassan R, Dombret H, Fielding A, Ribera JM, Buske C, et al. Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(Suppl 5):v69-v82.
4. Moorman AV, Chilton L, Wilkinson J, Ensor HM, Bown N, Proctor SJ. A population-based cytogenetic study of adults with acute lymphoblastic leukemia. Blood. 2010;115(2):206-14.
5. Lennmyr E, Karlsson K, Ahlberg L, Garelius H, Hulegardh E, Izarra AS, et al. Survival in adult acute lymphoblastic leukaemia (ALL): a report from the Swedish ALL Registry. Eur J Haematol. 2019;103(2):88-98.

6. Moorman AV, Harrison CJ, Buck GA, Richards SM, Secker-Walker LM, Martineau M, et al. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood. 2007;109(8):3189-97.

7. Aldoss I, Stiller T, Cao TM, Palmer JM, Thomas SH, Forman SJ, et al. Impact of additional cytogenetic abnormalities in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia undergoing allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2015;21(7):1326-9.

8. Short NJ, Kantarjian HM, Sasaki K, Ravandi F, Ko H, Cameron Yin C, et al. Poor outcomes associated with + der(22)(q)9;22) and −9/9p in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor. Am J Hematol. 2017;92(3):238-43.

9. Wetzler M, Dodge RK, Mrozek K, Stewart CC, Carroll AJ, Tantravahi R, et al. Additional cytogenetic abnormalities in adults with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a study of the Cancer and Leukaemia Group B. Br J Haematol. 2004;124(3):275-88.

10. Motllo C, Ribera JM, Morgades M, Granada I, Montesinos P, Mercedal S, et al. Frequency and prognostic significance of additional cytogenetic abnormalities to the Philadelphia chromosome in young and older adults with acute lymphoblastic leukemia. Leuk Lymphoma. 2018;59(1):146-54.

11. Lafage-Pochitaloff M, Baranger L, Hunault M, Cuccuini W, Lefebvre C, Bidet A, et al. Impact of cytogenetic abnormalities in adults with Ph-negative B-cell precursor acute lymphoblastic leukemia. Blood. 2017;130(16):1832-44.

12. Issa GC, Kantarjian HM, Yin CC, Qiao W, Ravandi F, Thomas D, et al. Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease. Cancer. 2017;123(3):459-67.

13. Stam RW, den Boer ML, Meijerink JP, Ebus ME, Peters GJ, Noordhuis P, et al. Differential mRNA expression of Ara-C-metabolizing enzymes explains Ara-C sensitivity in MLL gene-rearranged infant acute lymphoblastic leukemia. Blood. 2003;101(4):1270-6.

14. Chen Z, Sun Y, Xie W, Wang SA, Hu S, Li S, et al. Is hyperdiploidy a favorable cytogenetics in adults with B-lymphoblastic leukemia? Cancer Med. 2019;8(9):4093-9.

15. Motllo C, Ribera JM, Morgades M, Granada I, Montesinos P, Gonzalez-Campos J, et al. Prognostic significance of complex karyotype and monosomal karyotype in adult patients with acute lymphoblastic leukemia treated with risk-adapted protocols. Cancer. 2014;120(24):3958-64.

SUPPORTING INFORMATION
Additional supporting information may be found in the online version of the article at the publisher’s website.

How to cite this article: Lennmyr EB, Engvall M, Barbany G, Fogelstrand L, Rhodin H, Hallböök H. Cytogenetic aberrations in adult acute lymphoblastic leukemia—A population-based study. eJHaem. 2021;2:813–817.
https://doi.org/10.1002/jha2.300